Evidence map›Paper›PMID 34035920›Full record

ArticleSAGE open medical case reports2021

Successful combination chemotherapy involving clofarabine, cyclophosphamide, and etoposide for pediatric relapsed acute myeloid leukemia: A case report.

Sachio Fujita, Ryosuke Matsuno, Naoko Kawabata, Yumiko Sugishita, Ryota Kaneko, Masaya Koganesawa, Kosuke Akiyama, Daisuke Toyama, Shohei Yamamoto

Open access · goldAbstract readCase Reports
In one paragraph

Article in SAGE open medical case reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 44% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Sachio FujitaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Ryosuke MatsunoDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Naoko KawabataDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Yumiko SugishitaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Ryota KanekoDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.ORCID https://orcid.org/0000-0001-8158-6338
Masaya KoganesawaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Kosuke AkiyamaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Daisuke ToyamaDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.
Shohei YamamotoDepartment of Pediatrics, Showa University Fujigaoka Hospital, Yokohama, Japan.ORCID https://orcid.org/0000-0003-1582-7062
Showa University Fujigaoka Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Limited salvage chemotherapies are available for relapsed/refractory acute myeloid leukemia. Herein, we described successful reinduction chemotherapy, involving a combination of clofarabine, cyclophosphamide, and etoposide, in a 12-year-old male with relapsed acute myeloid leukemia prior to allogeneic bone marrow transplantation from his father. Although treatment with a combination of fludarabine, cytarabine, granulocyte colony-stimulating factor, idarubicin, and gemtuzumab ozogamicin had no positive effects, the aforementioned clofarabine-based chemotherapy induced complete remission and allowed the transplantation to go ahead. The abovementioned regimen may be useful for induction chemotherapy prior to hematopoietic stem cell transplantation for refractory/relapsed acute myeloid leukemia.

Indexed as

Clofarabinepediatricrelapsed acute myeloid leukemia

Identifiers

PMID34035920
PMCPMC8127742
OpenAlexW3162530256

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.